Haverford Trust Co Decreases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Haverford Trust Co cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 208,960 shares of the medical research company’s stock after selling 15,338 shares during the period. Haverford Trust Co’s holdings in Thermo Fisher Scientific were worth $108,707,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Legacy Investment Solutions LLC acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $26,000. Barrett & Company Inc. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. FPC Investment Advisory Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $28,000. Missouri Trust & Investment Co purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $29,000. Finally, Pillar Financial Advisors LLC purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on TMO. Raymond James restated an “outperform” rating and issued a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Citigroup cut their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Wells Fargo & Company increased their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Scotiabank increased their target price on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research report on Monday, February 3rd. Finally, StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $653.23.

Thermo Fisher Scientific Stock Down 0.1 %

Shares of NYSE TMO opened at $518.04 on Monday. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The stock has a market cap of $195.44 billion, a P/E ratio of 31.34, a PEG ratio of 2.99 and a beta of 0.79. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The business’s fifty day simple moving average is $546.15 and its 200-day simple moving average is $555.52.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.33%. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.41%.

Insider Activity at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock worth $13,106,062 over the last 90 days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.